U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07618078) titled 'RAIRI-Guided Adjuvant Therapy Benefit in Nasopharyngeal Cancer' on May 25.
Brief Summary: This prospective, multicenter, real-world observational study aims to evaluate whether a response-adaptive individualized risk index, the RAIRI model, can identify patients with non-metastatic nasopharyngeal carcinoma who may or may not benefit from adjuvant therapy after standard chemoradiotherapy. Patients will receive standard treatment according to routine clinical practice. After completion of chemoradiotherapy and assessment at approximately 1 month after radiotherapy, longitudinal multimodal response data, including plasma cfEBV DNA dynam...